Smruthi Organics Limited reported a significant turnaround in its financial performance for the first quarter of FY27, with net profit after tax (PAT) rising to ₹287.81 lakh for the quarter ended June 30, 2026. This marks a substantial improvement from the net loss of ₹109.54 lakh recorded in Q1FY26. The positive result was primarily driven by strong performance in its Bulk Drugs and Intermediates (API) division and the strategic discontinuance of its Formulations Marketing Division.

The Board of Directors approved the unaudited financial results at a meeting held on August 10, 2026, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Gokhale & Sathe Chartered Accountants, who issued an unmodified moderate assurance report. The filing highlights that the Formulations Division was classified as a discontinued operation effective May 13, 2026, with its residual assets under recovery.

Financial Performance Highlights

Revenue from operations grew by 55.4% year-on-year to ₹2930.22 lakh in Q1FY27, up from ₹1885.31 lakh in Q1FY26. This growth outpaced the previous quarter’s revenue of ₹2905.45 lakh, indicating sustained momentum. Total income stood at ₹2932.78 lakh, including other income of ₹2.56 lakh.

The company managed to control expenses effectively despite the revenue surge. Cost of materials consumed increased to ₹1392.45 lakh from ₹1200.78 lakh in the prior year, reflecting higher production volumes. Employee benefit expenses remained stable at ₹449.02 lakh. Notably, finance costs decreased to ₹31.10 lakh from ₹46.18 lakh in Q1FY26, contributing to improved profitability. Depreciation and amortization expenses were recorded at ₹160.15 lakh.

Segment-Wise Analysis

With the discontinuance of the Formulations Marketing Division, the API segment now represents the sole operating segment of the company. The API division generated revenue of ₹2931.96 lakh in Q1FY27, up from ₹1893.58 lakh in Q1FY26. The segment’s result before interest and taxes (EBIT) improved dramatically to ₹419.64 lakh from a loss of ₹53.21 lakh in the corresponding period last year.

The discontinued Formulations Division reported a loss before tax of ₹8.82 lakh in Q1FY27, compared to a loss of ₹7.17 lakh in Q1FY26. As per Ind AS 105, the results of this division are presented separately. Unallocable costs of ₹72.57 lakh and interest expense of ₹22.09 lakh related to the discontinued division have been presented within the API segment for the current quarter, while comparatives have not been restated.

What the Numbers Show

The most critical insight from Smruthi Organics’ Q1FY27 results is the operational efficiency gained by shedding the loss-making Formulations unit. While revenue growth of 55% is robust, the shift in profit dynamics is more pronounced: the company moved from a pre-tax loss of ₹148.16 lakh to a profit of ₹392.88 lakh. This turnaround was not solely due to top-line growth but also benefited from reduced finance costs and the elimination of drag from the Formulations segment. The API segment’s EBIT margin expanded significantly, suggesting that the core business is scaling efficiently. Investors should monitor whether the integration of unallocable costs into the API segment will impact future margin visibility or if these costs will decline as the Formulations wind-down completes.

Smruthi Organics Limited will hold its 37th Annual General Meeting on August 10, 2026, via video conferencing to transact business including the adoption of financial statements for the year ended March 31, 2026. The meeting, scheduled to commence at 2:30 p.m. IST, will be conducted without the physical presence of shareholders at a common venue in compliance with Ministry of Corporate Affairs and SEBI circulars. The company has fixed Friday, July 31, 2026, as the record date to determine shareholder eligibility for the dividend and participation in the meeting.

The Board proposes a dividend of ₹1.50 per share, equivalent to 15%, on 1,14,46,290 equity shares of ₹10 each for the financial year 2025-2026. Shareholders will consider the adoption of the audited financial statements, including the Balance Sheet, Statement of Profit & Loss, and Cash Flow Statement, along with the reports of the Board of Directors and Auditors. The register of members and share transfer books will remain closed from August 1, 2026, to August 10, 2026, for the purpose of the AGM and dividend determination.

Key Resolutions

The meeting features five resolutions, covering ordinary and special business. The ordinary business includes the adoption of accounts, dividend declaration, and the appointment of a director in place of Mr. Swapnil Eaga, who retires by rotation and is eligible for re-appointment. The special business includes the ratification of remuneration for the Cost Auditor and the appointment of Ms. Smruthi Eaga as Whole-time Director.

Director Appointment and Remuneration

Shareholders will vote on a special resolution to appoint Ms. Smruthi Eaga as Whole-time Director (Executive) for a period of three years from June 1, 2026, to May 31, 2029. Ms. Eaga, currently a Non-Executive (Non-Independent) Director, will receive a remuneration of ₹7 lakhs per month, totaling ₹84 lakhs per annum, plus allowances, benefits, and perquisites. The Board is authorized to grant annual increments not exceeding 15% of the relevant remuneration. The appointment requires approval from the members and the Central Government, as Ms. Eaga is currently not a resident of India.

The resolution also seeks ratification for the remuneration of the Cost Auditor, Shrinivas Diddi & Associates, for the audit of cost records for the financial year ending March 31, 2027. The fees are set at ₹55,000 plus applicable GST and reimbursement of out-of-pocket expenses. Mr. H.R. Thakur, Practicing Company Secretary, has been appointed as the scrutinizer to conduct the e-voting process.

Financial Performance

For the financial year ended March 31, 2026, Smruthi Organics reported a Profit After Tax of ₹342.57 lakh. Net sales and other income stood at ₹10,209.06 lakh, while total expenses amounted to ₹9,696.37 lakh. The company reported a profit before tax of ₹466.43 lakh, with a tax expense of ₹123.86 lakh. The profitability was impacted by lower sales revenue, geopolitical uncertainties, and an exceptional charge relating to the statutory impact of new Labour Codes.